We’re pleased to share that Koru Pharma has been featured in the Chinese edition of Aju Business Daily, spotlighting our accelerating growth and strategic direction.

In Q3, our sales reached 24.86 billion KRW, a 4.8% year-on-year increase, while operating profit rose 47.2% to 5.44 billion KRW. We anticipate full-year revenue to surpass 40 billion KRW, marking a significant milestone in our development.

Building on this momentum, we are now preparing for an IPO in 2026.

Koru Pharma’s core strength lies in its fully integrated model - in-house R&D, advanced manufacturing, and a diverse, high-quality product portfolio that allows us to deliver tailored solutions for each market. Since our establishment, we have maintained consistent growth, from over 80% in the early years to around 10% in recent periods.

Our current focus is on deepening our presence across East Asia, particularly in China, Korea, and Japan.

In China, our flagship AVALON™ HA fillers line is undergoing clinical trials, expected to be completed within this year - an essential step toward entering this key market.

At the same time, we continue strengthening our domestic footprint in Korea and expanding into Japan, unlocking new opportunities across the region.

📖 Read the full interview